CABA vs BLFY Comparison

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Blue Foundry Bancorp is a full-service bank. Its business consists of originating one-to-four-family residential, multi-family, and non-residential real estate mortgages, home equity loans and lines of credit, and commercial and industrial loans. It attracts retail deposits from the general public in the areas surrounding its banking offices, through its borrowers, and through its online presence, offering a wide variety of deposit products. The bank also invests in securities. Its revenues are derived from interest on loans and, to a lesser extent, interest on mortgage-backed and other investment securities. The company's sources of funds are deposits, principal, and interest payments on loans, securities, and borrowings from the Federal Home Loan Bank of New York.